Study population
Symptomatic patients with monomorphic RVOT-type VAs and refractory to at least one antiarrhythmic agent were eligible. Patients were excluded if they had structural heart disease or successful ablation outside RVOT. Written informed consents were provided before the procedures. The study was approved by the ethics committee of Guizhou Provincial People’s Hospital.